Imperial College London

Professor Neil Poulter

Faculty of MedicineNational Heart & Lung Institute

Professor of Preventive Cardiovascular Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 3446n.poulter

 
 
//

Assistant

 

Mrs Ranjit Rayat +44 (0)20 7594 3445

 
//

Location

 

55Stadium HouseWhite City

//

Summary

 

Publications

Publication Type
Year
to

516 results found

Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Ohman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RRet al., 2018, Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis, LANCET DIABETES & ENDOCRINOLOGY, Vol: 6, Pages: 105-113, ISSN: 2213-8587

JOURNAL ARTICLE

Dzudie A, Rayner B, Ojji D, Schutte AE, Twagirumukiza M, Damasceno A, Ba SA, Kane A, Kramoh E, Anzouan Kacou JB, Onwubere B, Cornick R, Sliwa K, Anisiuba B, Mocumbi AO, Ogola E, Awad M, Nel G, Otieno H, Toure AI, Kingue S, Kengne AP, Perel P, Adler A, Poulter N, Mayosi B, PASCAR Task Force on Hypertensionet al., 2018, Roadmap to Achieve 25% Hypertension Control in Africa by 2025., Glob Heart, Vol: 13, Pages: 45-59

BACKGROUND: The Pan-African Society of Cardiology (PASCAR) has identified hypertension as the highest area of priority action to reduce heart disease and stroke on the continent. OBJECTIVES: The aim of this PASCAR roadmap on hypertension was to develop practical guidance on how to implement strategies that translate existing knowledge into effective action and improve detection, treatment and control of hypertension and cardiovascular health in sub-Saharan Africa (SSA) by the year 2025. METHODS: Development of this roadmap started with the creation of a consortium of experts with leadership skills in hypertension. In 2014, experts in different fields, including physicians and nonphysicians, were invited to join. Via face-to-face meetings and teleconferences, the consortium made a situation analysis, set a goal, identified roadblocks and solutions to the management of hypertension and customized the World Heart Federation roadmap to Africa. RESULTS: Hypertension is a major crisis on the continent but very few randomized controlled trials have been conducted on its management. Also, only 25.8% of the countries have developed or adopted guidelines for management of hypertension. Other major roadblocks are either government and health-system related or health care professional or patient related. The PASCAR hypertension task force identified a 10-point action plan to be implemented by African ministries of health to achieve 25% control of hypertension in Africa by 2025. CONCLUSIONS: Hypertension affects millions of people in SSA and if left untreated, is a major cause of heart disease and stroke. Very few SSA countries have a clear hypertension policy. This PASCAR roadmap identifies practical and effective solutions that would improve detection, treatment and control of hypertension on the continent and could be implemented as is or adapted to specific national settings.

JOURNAL ARTICLE

Jun M, Ohkuma T, Zoungas S, Colagiuri S, Mancia G, Marre M, Matthews D, Poulter N, Williams B, Rodgers A, Perkovic V, Chalmers J, Woodward M, ADVANCE Collaborative Groupet al., 2018, Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON., Diabetes Care, Vol: 41, Pages: 163-170

OBJECTIVE: To assess the association between 2-year changes in urine albumin-to-creatinine ratio (UACR) and the risk of clinical outcomes in type 2 diabetes. RESEARCH DESIGN AND METHODS: We analyzed data from 8,766 participants in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Post-Trial Observational Study (ADVANCE-ON). Change in UACR was calculated from UACR measurements 2 years apart, classified into three groups: decrease in UACR of ≥30%, minor change, and increase in UACR of ≥30%. By analyzing changes from baseline UACR groups, categorized into thirds, we repeated these analyses accounting for regression to the mean (RtM). The primary outcome was the composite of major macrovascular events, renal events, and all-cause mortality; secondary outcomes were these components. Cox regression models were used to estimate hazard ratios (HRs). RESULTS: Over a median follow-up of 7.7 years, 2,191 primary outcomes were observed. Increases in UACR over 2 years independently predicted a greater risk of the primary outcome (HR for ≥30% UACR increase vs. minor change: 1.26; 95% CI 1.13-1.41), whereas a decrease in UACR was not significantly associated with lower risk (HR 0.93; 95% CI 0.83-1.04). However, after allowing for RtM, the effect of "real" decrease in UACR on the primary outcome was found to be significant (HR 0.84; 95% CI 0.75-0.94), whereas the estimated effect on an increase was unchanged. CONCLUSIONS: Changes in UACR predicted changes in the risk of major clinical outcomes and mortality in type 2 diabetes, supporting the prognostic utility of monitoring albuminuria change over time.

JOURNAL ARTICLE

Mohammedi K, Chalmers J, Herrington W, Li Q, Mancia G, Marre M, Poulter N, Rodgers A, Williams B, Perkovic V, Coresh J, Woodward Met al., 2018, Associations between body mass index and the risk of renal events in patients with type 2 diabetes., Nutr Diabetes, Vol: 8

BACKGROUND/OBJECTIVES: We aimed to evaluate the relationship between BMI and the risk of renal disease in patients with type 2 diabetes in the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation (ADVANCE) study. SUBJECTS/METHODS: Participants were divided into six baseline BMI categories: <18.5 (underweight, n = 58); ≥18.5 to <25 (normal, n = 2894); ≥25 to <30 (overweight, n = 4340); ≥30 to <35 (obesity grade 1, n = 2265); ≥35 to <40 (obesity grade 2, n = 744); and ≥40 kg/m2 (obesity grade 3, n = 294); those underweight were excluded. The composite outcome "major renal event" was defined as development of new macroalbuminuria, doubling of creatinine, end stage renal disease, or renal death. These outcomes and development of new microalbuminuria were considered individually as secondary endpoints. RESULTS: During 5-years of follow-up, major renal events occurred in 487 (4.6%) patients. The risk increased with higher BMI. Multivariable-adjusted HRs (95% CIs), compared to normal weight, were: 0.91 (0.72-1.15) for overweight; 1.03 (0.77-1.37) for obesity grade 1; 1.42 (0.98-2.07) for grade 2; and 2.16 (1.34-3.48) for grade 3 (p for trend = 0.006). These findings were similar across subgroups by randomised interventions (intensive versus standard glucose control and perindopril-indapamide versus placebo). Every additional unit of BMI over 25 kg/m2 increased the risk of major renal events by 4 (1-6)%. Comparable results were observed with the risk of secondary endpoints. CONCLUSIONS: Higher BMI is an independent predictor of major renal events in patients with type 2 diabetes. Our findings encourage weight loss to improve nephroprotection in these patients.

JOURNAL ARTICLE

Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cifkova R, Dominiczak AF, Grassi G, Jordan J, Poulter NR, Rodgers A, Whelton PKet al., 2018, Hypertension, NATURE REVIEWS DISEASE PRIMERS, Vol: 4, ISSN: 2056-676X

JOURNAL ARTICLE

Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pratley RE, Woo V, Heller S, Lange M, Brown-Frandsen K, Moses A, Lekdorf JB, Lehmann L, Kvist K, Buse JBet al., 2018, DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality, DIABETOLOGIA, Vol: 61, Pages: 58-65, ISSN: 0012-186X

JOURNAL ARTICLE

Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Lange M, Brown-Frandsen K, Moses A, Francisco AMO, Lekdorf JB, Kvist K, Buse JBet al., 2018, Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2), DIABETOLOGIA, Vol: 61, Pages: 48-57, ISSN: 0012-186X

JOURNAL ARTICLE

Atkins ER, Hirakawa Y, Salam A, Woodward M, Cooper M, Hamet P, Harrap S, Lees K, Liu L, Mancia G, Marre M, Perkovic V, Poulter N, Williams B, Chalmers J, Rodgers Aet al., 2017, Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials, JOURNAL OF HYPERTENSION, Vol: 35, Pages: 1318-1325, ISSN: 0263-6352

JOURNAL ARTICLE

Blomster JI, Zoungas S, Woodward M, Neal B, Harrap S, Poulter N, Marre M, Williams B, Chalmers J, Hillis GSet al., 2017, The impact of level of education on vascular events and mortality in patients with type 2 diabetes mellitus: Results from the ADVANCE study, DIABETES RESEARCH AND CLINICAL PRACTICE, Vol: 127, Pages: 212-217, ISSN: 0168-8227

JOURNAL ARTICLE

Bunker J, Chang C-L, Chapman N, Poulter N, Thom S, Thornton-Jones L, Sever Pet al., 2017, True Resistant Hypertension Following Observed Drug Ingestion: A Systematic Evaluation, JOURNAL OF CLINICAL HYPERTENSION, Vol: 19, Pages: 250-255, ISSN: 1524-6175

JOURNAL ARTICLE

Crossan C, Dehbi H-M, Williams H, Poulter N, Thom S, Lord Jet al., 2017, Economic evaluation of a polypill for the treatment of patients with established or at high risk of cardiovascular disease (CVD): a UK-National Health Service study, Publisher: NATURE PUBLISHING GROUP, Pages: 664-664, ISSN: 0950-9240

CONFERENCE PAPER

Crossan CJ, Dehbi H, Thom S, Poulter N, Lord Jet al., 2017, COST-EFFECTIVENESS OF A POLYPILL FOR PATIENTS WITH OR AT HIGH RISK OF CARDIOVASCULAR DISEASE IN AN NHS SETTING, Publisher: ELSEVIER SCIENCE INC, Pages: A620-A620, ISSN: 1098-3015

CONFERENCE PAPER

Glaysher MA, Mohanaruban A, Prechtl CG, Goldstone AP, Miras AD, Lord J, Chhina N, Falaschetti E, Johnson NA, Al-Najim W, Smith C, Li JV, Patel M, Ahmed AR, Moore M, Poulter N, Bloom S, Darzi A, Le Roux C, Byrne JP, Teare JPet al., 2017, A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus, BMJ OPEN, Vol: 7, ISSN: 2044-6055

JOURNAL ARTICLE

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Groupet al., 2017, Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes., N Engl J Med, Vol: 377, Pages: 1228-1239

BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those

JOURNAL ARTICLE

Kraja AT, Cook JP, Warren HR, Surendran P, Liu C, Evangelou E, Manning AK, Grarup N, Drenos F, Sim X, Smith AV, Amin N, Blakemore AIF, Bork-Jensen J, Brandslund I, Farmaki A-E, Fava C, Ferreira T, Herzig K-H, Giri A, Giulianini F, Grove ML, Guo X, Harris SE, Have CT, Havulinna AS, Zhang H, Jorgensen ME, Karajamaki A, Kooperberg C, Linneberg A, Little L, Liu Y, Bonnycastle LL, Lu Y, Magi R, Mahajan A, Malerba G, Marioni RE, Mei H, Menni C, Morrison AC, Padmanabhan S, Palmas W, Poveda A, Rauramaa R, Rayner NW, Riaz M, Rice K, Richard MA, Smith JA, Southam L, Stancakova A, Stirrups KE, Tragante V, Tuomi T, Tzoulald I, Varga TV, Weiss S, Yiorkas AM, Young R, Zhang W, Barnes MR, Cabrera CP, Gao H, Boehnke M, Boerwinkle E, Chambers JC, Connell JM, Christensen CK, de Boer RA, Deary IJ, Dedoussis G, Deloukas P, Dominiczak AF, Dorr M, Joehanes R, Edwards TL, Esko T, Fornage M, Franceschini N, Franks PW, Gambaro G, Groop L, Hallmans G, Hansen T, Hayward C, Heikki O, Ingelsson E, Tuomilehto J, Jarvelin M-R, Kardia SLR, Karpe F, Kooner JS, Lakka TA, Langenberg C, Lind L, Loos RJF, Laakso M, McCarthy MI, Melander O, Mohlke KL, Moris AP, Palmer CNA, Pedersen O, Polasek O, Poulter NR, Province MA, Psaty BM, Ridker PM, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sever PJ, Skaaby T, Stafford JM, Starr JM, van der Harst P, van der Meer P, van Duijn CM, Vergnaud A-C, Gudnason V, Wareham NJ, Wilson JG, Willer CJ, Witte DR, Zeggini E, Saleheen D, Butterworth AS, Danesh J, Asselbergs FW, Wain LV, Ehret GB, Chasman DI, Caulfield MJ, Elliott P, Lindgren CM, Levy D, Newton-Cheh C, Munroe PB, Howson JMMet al., 2017, New Blood Pressure-Associated Loci Identified in Meta-Analyses of 475000 Individuals, CIRCULATION-CARDIOVASCULAR GENETICS, Vol: 10, ISSN: 1942-325X

JOURNAL ARTICLE

Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, Saleheen D, Emdin C, Alam D, Alves AC, Amouyel P, Di Angelantonio E, Arveiler D, Assimes TL, Auer PL, Baber U, Ballantyne CM, Bang LE, Benn M, Bis JC, Boehnke M, Boerwinkle E, Bork-Jensen J, Bottinger EP, Brandslund I, Brown M, Busonero F, Caulfield MJ, Chambers JC, Chasman DI, Chen YE, Chen Y-DI, Chowdhury R, Christensen C, Chu AY, Connell JM, Cucca F, Cupples LA, Damrauer SM, Davies G, Deary IJ, Dedoussis G, Denny JC, Dominiczak A, Dube M-P, Ebeling T, Eiriksdottir G, Esko T, Farmaki A-E, Feitosa MF, Ferrario M, Ferrieres J, Ford I, Fornage M, Franks PW, Frayling TM, Frikke-Schmidt R, Fritsche LG, Frossard P, Fuster V, Ganesh SK, Gao W, Garcia ME, Gieger C, Giulianini F, Goodarzi MO, Grallert H, Grarup N, Groop L, Grove ML, Gudnason V, Hansen T, Harris TB, Hayward C, Hirschhorn JN, Holmen OL, Huffman J, Huo Y, Hveem K, Jabeen S, Jackson AU, Jakobsdottir J, Jarvelin M-R, Jensen GB, Jorgensen ME, Jukema JW, Justesen JM, Kamstrup PR, Kanoni S, Karpe F, Kee F, Khera AV, Klarin D, Koistinen HA, Kooner JS, Kooperberg C, Kuulasmaa K, Kuusisto J, Laakso M, Lakka T, Langenberg C, Langsted A, Launer LJ, Lauritzen T, Liewald DCM, Lin LA, Linneberg A, Loos RJF, Lu Y, Lu X, Magi R, Malarstig A, Manichaikul A, Manning AK, Mantyselka P, Marouli E, Masca NGD, Maschio A, Meigs JB, Melander O, Metspalu A, Morris AP, Morrison AC, Mulas A, Mueller-Nurasyid M, Munroe PB, Neville MJ, Nielsen JB, Nielsen SF, Nordestgaard BG, Ordovas JM, Mehran R, O'Donnell CJ, Orho-Melander M, Molony CM, Muntendam P, Padmanabhan S, Palmer CNA, Pasko D, Patel AP, Pedersen O, Perola M, Peters A, Pisinger C, Pistis G, Polasek O, Poulter N, Psaty BM, Rader DJ, Rasheed A, Rauramaa R, Reilly DF, Reiner AP, Renstrom F, Rich SS, Ridker PM, Rioux JD, Robertson NR, Roden DM, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sanna S, Sattar N, Schmidt EM, Scott RA, Sever P, Sevilla RS, Shaffer CM, Sim X, Sivapalaratnam S, Small KS, Smith AV, Smith BH, Somayajulaet al., 2017, Exome-wide association study of plasma lipids in > 300,000 individuals, NATURE GENETICS, Vol: 49, Pages: 1758-+, ISSN: 1061-4036

JOURNAL ARTICLE

Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornoe K, Zinman B, Buse JBet al., 2017, Liraglutide and Renal Outcomes in Type 2 Diabetes, NEW ENGLAND JOURNAL OF MEDICINE, Vol: 377, Pages: 839-848, ISSN: 0028-4793

JOURNAL ARTICLE

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr P-M, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JBet al., 2017, Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes, NEW ENGLAND JOURNAL OF MEDICINE, Vol: 377, Pages: 723-732, ISSN: 0028-4793

JOURNAL ARTICLE

Mentz RJ, Bethel MA, Gustavson S, Thompson VP, Pagidipati NJ, Buse JB, Chan JC, Iqbal N, Maggioni AP, Marso SP, Olunan P, Poulter N, Ramachandran A, Zinman B, Hernandez AF, Holman RRet al., 2017, Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL), AMERICAN HEART JOURNAL, Vol: 187, Pages: 1-9, ISSN: 0002-8703

JOURNAL ARTICLE

Messerli FH, Hofstetter L, Agabiti-Rosei E, Burnier M, Elliott WJ, Franklin SS, Grodzicki T, Kario K, Kjeldsen SE, Kostis JB, Laurent S, Leenen FH, Lund-Johansen P, Mancia G, Narkiewicz K, Papademetriou V, Parati G, Poulter N, Redon J, Rimoldi SF, Ruilope LM, Schiffrin EL, Schmieder RE, Schwartz AB, Sever P, Sowers JR, Staessen JA, Wang J, Weber M, Williams Bet al., 2017, No Longer a Sine Qua Non for Guideline Authors?, HYPERTENSION, Vol: 70, Pages: 235-237, ISSN: 0194-911X

JOURNAL ARTICLE

Messerli FH, Hofstetter L, Agabiti-Rosei E, Burnier M, Elliott WJ, Franklin SS, Grodzicki T, Kario K, Kjeldsen SE, Kostis JB, Laurent S, Leenen FH, Lund-Johansen P, Mancia G, Narkiewicz K, Papademetriou V, Parati G, Poulter N, Redon J, Rimoldi SF, Ruilope LM, Schiffrin EL, Schmieder RE, Schwartz AB, Sever P, Sowers JR, Staessen JA, Wang J, Weber M, Williams B, de Leeuw PWet al., 2017, Expertise: no longer a sine qua non for guideline authors?, JOURNAL OF HYPERTENSION, Vol: 35, Pages: 1564-1566, ISSN: 0263-6352

JOURNAL ARTICLE

Messerli FH, Hofstetter L, Agabiti-Rosei E, Burnier M, Elliott WJ, Franklin SS, Grodzicki T, Kario K, Kjeldsen SE, Kostis JB, Laurent S, Leenen FH, de Leeuw PW, Lund-Johansen P, Mancia G, Narkiewicz K, Papademetriou V, Parati G, Poulter N, Redon J, Rimoldi SF, Ruilope LM, Schiffrin EL, Schmieder RE, Schwartz AB, Sever P, Sowers JR, Staessen JA, Wang J, Weber M, Williams Bet al., 2017, Who is an expert? Reply, JOURNAL OF HYPERTENSION, Vol: 35, Pages: 2327-2328, ISSN: 0263-6352

JOURNAL ARTICLE

Mohammedi K, Woodward M, Marre M, Colagiuri S, Cooper M, Harrap S, Mancia G, Poulter N, Williams B, Zoungas S, Chalmers Jet al., 2017, Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes, CARDIOVASCULAR DIABETOLOGY, Vol: 16, ISSN: 1475-2840

JOURNAL ARTICLE

Noordam R, Sitlani CM, Avery CL, Stewart JD, Gogarten SM, Wiggins KL, Trompet S, Warren HR, Sun F, Evans DS, Li X, Li J, Smith AV, Bis JC, Brody JA, Busch EL, Caulfield MJ, Chen Y-DI, Cummings SR, Cupples LA, Duan Q, Franco OH, Mendez-Giraldez R, Harris TB, Heckbert SR, van Heemst D, Hofman A, Floyd JS, Kors JA, Launer LJ, Li Y, Li-Gao R, Lange LA, Lin HJ, de Mutsert R, Napier MD, Newton-Cheh C, Poulter N, Reiner AP, Rice KM, Roach J, Rodriguez CJ, Rosendaal FR, Sattar N, Sever P, Seyerle AA, Slagboom PE, Soliman EZ, Sotoodehnia N, Stott DJ, Stumer T, Taylor KD, Thornton TA, Uitterlinden AG, Wilhelmsen KC, Wilson JG, Gudnason V, Jukema JW, Laurie CC, Liu Y, Mook-Kanamori DO, Munroe PB, Rotter JI, Vasan RS, Psaty BM, Stricker BH, Whitsel EAet al., 2017, A genome-wide interaction analysis of tricyclic/tetracyclic antidepressants and RR and QT intervals: a pharmacogenomics study from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, JOURNAL OF MEDICAL GENETICS, Vol: 54, Pages: 313-323, ISSN: 0022-2593

JOURNAL ARTICLE

Ohkuma T, Woodward M, Jun M, Muntner P, Hata J, Colagiuri S, Harrap S, Mancia G, Poulter N, Williams B, Rothwell P, Chalmers Jet al., 2017, Prognostic Value of Variability in Systolic Blood Pressure Related to Vascular Events and Premature Death in Type 2 Diabetes Mellitus The ADVANCE-ON Study, HYPERTENSION, Vol: 70, Pages: 461-+, ISSN: 0194-911X

JOURNAL ARTICLE

Poulter N, Mann JFE, Brown-Frandsen K, Daniels GH, Kristensen P, Nauck MA, Nissen SE, Pocock S, Buse JB, Petrie Jet al., 2017, Liraglutide and renal outcomes in Type 2 diabetes: results of the 'Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results' (LEADER) trial, DIABETIC MEDICINE, Vol: 34, Pages: 23-24, ISSN: 0742-3071

JOURNAL ARTICLE

Poulter NR, Lackland DT, 2017, May Measurement Month: a global blood pressure screening campaign, LANCET, Vol: 389, Pages: 1678-1680, ISSN: 0140-6736

JOURNAL ARTICLE

Poulter NR, Schutte AE, Tomaszewski M, Lackland DTet al., 2017, May Measurement Month: a new joint global initiative by the International Society of Hypertension and the World Hypertension League to raise awareness of raised blood pressure, JOURNAL OF HYPERTENSION, Vol: 35, Pages: 1126-1128, ISSN: 0263-6352

JOURNAL ARTICLE

Stam-Slob MC, Visseren FLJ, Jukema JW, van der Graaf Y, Poulter NR, Gupta A, Sattar N, Macfarlane PW, Kearney PM, de Craen AJM, Trompet Set al., 2017, Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients, CLINICAL RESEARCH IN CARDIOLOGY, Vol: 106, Pages: 58-68, ISSN: 1861-0684

JOURNAL ARTICLE

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00160059&limit=30&person=true